Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine
Ovarian cancer (OC) has the highest mortality rate of all gynecological malignancies due to the high prevalence of advanced stages of diagnosis and the high rate of recurrence. Furthermore, the heterogeneity of OC tumors contributes to the rapid development of resistance to conventional chemotherapy...
Main Authors: | Giulia Spagnol, Francesca Sensi, Orazio De Tommasi, Matteo Marchetti, Giulio Bonaldo, Livia Xhindoli, Marco Noventa, Marco Agostini, Roberto Tozzi, Carlo Saccardi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/7/2059 |
Similar Items
-
Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours
by: P. Fusco, et al.
Published: (2019-10-01) -
Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models
by: Ergang Wang, et al.
Published: (2022-12-01) -
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
by: Zilong Zhou, et al.
Published: (2021-12-01) -
Organoid and organoid extracellular vesicles for osteoporotic fractures therapy: Current status and future perspectives
by: Han Liu, et al.
Published: (2023-07-01) -
Human Organoids for Predictive Toxicology Research and Drug Development
by: Toshikatsu Matsui, et al.
Published: (2021-11-01)